Duovas is indicated for the treatment of hypertension, alone or with other antihypertensive agents. Duovas may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
The usual starting dose of Duovas is 5/20 mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum dose of 10/40 mg once daily as needed to control blood pressure. Duovas may be taken with or without food. Duovas may be administered with other antihypertensive agents. Initial therapy with this combination product is not recommended in patient â‰¥ 75 years old or with hepatic impairment.
Duovas may be substituted for its individually titrated components. When substituting for individual components, the dose of one or both of the components can be increased if blood pressure control has not been satisfactory.
Duovas may be used to provide additional blood pressure lowering for patients not adequately controlled with Amlodipine (or another dihydropyridine calcium channel antagonist) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone.
Aliskiren is contraindicated with Duovas in patients with diabetes.
The reported adverse reactions were generally mild and seldom led to discontinuation of treatment. The most common side effects include edema, dizziness, flushing and palpitation. Other side effects may include vomiting, diarrhoea, louboutin damenschuhe, rhabdomyolysis, alopecia, pruritus, urticaria etc.
Pregnancy: When pregnancy is detected, discontinue this combination product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.
Nursing Mothers: Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
As a consequence of inhibiting the renin- angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan medoxomil. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with olmesartan medoxomil.
Store in a cool and dry place, protect from light and moisture.
Keep out of the reach of children.